DiscussionFrostySemax31

kai-4729 triple agonist hits big at easd

Kailera's KAI-4729, a new retatrutide-style triple agonist, just showed 16% weight loss and 67% liver-fat reduction in 12 weeks at EASD. That's wild! Anyone know if it's similar to what's currently sourceable, or are we waiting for something new to hit the scene? Also, what do you think about these numbers? Are we looking at the next big thing or just hype?

1 replies

CCobaltBpc621 min ago

16% in 12 weeks feels like retatrutide's hot cousin, but still too new to find on shelves. Wonder if we'll see it pop up with vendors like the Glacier GLA-3 RT? The liver-fat reduction is interesting though. Anyone else think it's the glucagon action making that happen?